63 research outputs found
Lightening of ceramic bricks based on red-burning clay
To determine the possibility of using a mineral pigment based on the rutile form of titanium dioxide in the production of volume-colored ceramic brick in order to obtain lighter brick tones the studies are conducted. The previously studied low-melting clay of the Tyumen deposit was used as a basis. It was established that significant lightening of the brick does not occur even with the introduction of 8% of the specified pigment, although some lightening is appeared. In addition, with the pigment introduction, an increase in water absorption of bricks is observed, which leads to a decrease in the sample strength. Increasing the firing temperature to 950°C does not lead to an improvement in the quality characteristics of the samples, and even vice versa makes them worse. Thus, the use of a white pigment under investigation does not give a significant effect of lightening of ceramic red-burning clay. © 2019 IOP Publishing Ltd. All rights reserved
RESEARCH OF OVERLAY CLAY ROCKS PROPERTIES IN ORDER TO DETERMINE THEIR SUITABILITY IN THE PRODUCTION OF CERAMIC MATERIALS
Рассмотрена возможность утилизации вскрышных глинистых пород, образующихся при добыче доломита. Представлены свойства глины (химический и минеральный состав) и образцов керамики, полученной на основе этой глины. Установлено, что технология производства керамики на основе исследуемой вскрышной породы должна включать обязательное измельчение глины до размера частиц менее 0,5 мм. По предложенной технологии производства на основе это глины возможно получение лицевого строительного кирпича и керамической черепицы с морозостойкостью более 100 циклов, а также получение гончарных непроницаемых изделий.The possibility of utilization of overburden clay rocks formed during the extraction of dolomite is considered. The paper presents the properties of clay and ceramic samples obtained on the clay basis. It was found that for the manufacture of ceramics, clay should be crushed to a particle size of less than 0.5 mm. According to the proposed technology, it is possible to obtain front ceramic bricks, ceramic tiles with high frost resistance, as well as impervious pottery
ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION
Aim. To evaluate by modelling the economic benefits of left ventricular hypertrophy (LVH) regression in patients with arterial hypertension (HT) due to therapy with fixed combination of valsartan/amlodipine. Material and methods. 20 patients (15 females and 5 males, aged 18 to 70 years) with essential HT accompanied by metabolic syndrome with a history of previous ineffective antihypertensive therapy were included into the study. All patients were treated with fixed combination of amlodipine/valsartan in doses of 5/160 and 10/160 mg depending on blood pressure (BP) level. Treatment duration was 24 weeks. Changes in BP level, LVH regression were assessed. Economic evaluation was performed on the basis of modelling with the specialized software Decision Tree 4.xla. Results. Effect of fixed amlodipine/valsartan combination therapy on LVH was used to estimate treatment effectiveness and to build the model. Patients were distributed according to left ventricular (LV) mass (at baseline and after 24 weeks of therapy). Significant decrease in LV mass from 205.8±50.4 to 181.9±45.1 g (p<0.05) was revealed. The model took into account economic and frequency factors for 10 year prognosis: this therapy prevents 36 deaths, 6 strokes, 24 myocardial infarction per 1000 patients. Absence of need in treatment of these prevented events can save 2 516 772.42 RUR for every 1 000 patients. It would reduce the total costs per patient during 10 years. Conclusion. Treatment with amlodipine/valsartan single pill combination has not only clinical advantages, but also pharmacoeconomic benefits. This combination reduces risk of acute myocardial infarction and death more effectively. Treatment with fixed valsartan/amlodipine combination saves maximum years of life with less cost during 10 years. Despite of higher pharmacotherapy costs, fixed valsartan/amlodipine combination reduces total costs due to prevention of fatal and nonfatal cardiovascular events
Azoloazines as Perspective Antiglycating Agents for Therapy of Diabetes Complications
This work was supported by Russian Federation Ministry of education and science (grant № 4.6351.2017/8.9) and Russian Foundation for Basic Research (grant № 18-03-00787)
TREATMENT EFFICIENCY OF DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS
The article describes the study of comparative efficiency of fenazid (isonicotinoilhydrazine-О,N’) ferrous dihydrate sulphate (II) and isoniazid in drug susceptible pulmonary tuberculosis patients.The high treatment efficiency namely significant improvement and improvement was observed in the patients of Group 1 – 84.1% which could be compared to the standard treatment regimen (85-7%) in Group 2. The total number of adverse reactions in the main group was confidently lower – 18.6% against 33.9%, p < 0.05. Hepatotoxic reactions with 2-3 fold increase of alaninetransferase level was registered significantly less (9.3%) in Group 1 compared to the Group treated with isoniazid
New antiglycating agents for diabetes therapy
It was shown that azoloazines (1) demonstrated higher antiglycation activity than reference compound, aminoguanidine, and have some potential as dipeptidylpeptidase-4 inhibitors. By given results this class of heterocycles can be considered as candidate for extended studies to develop drugs against complications of T2DM [1-4].The work was supported by the Ministry of Education and Science of Russia (grant №0836-2020-0058)
Современные подходы к введению показателя «Аномальная токсичность»
For over 60 years, the Abnormal Toxicity Test (ATT) has been used as an important tool in safety control of some parenteral and veterinary products made from biological materials. In 2017, some of the members of the Pharmacopoeial Committee of the Eurasian Economic Union (EAEU) proposed not to include the ATT in the draft monographs of the EAEU Pharmacopoeia based on the decision of the European Pharmacopoeia Commission to suppress the test. However, this may not be achieved in Russia at this point, because some production sites that manufacture medicinal products for human and veterinary use have not fully implemented GMP principles yet. The main aim of the ATT is to detect any toxicity above the pre-determined acceptable level. The unacceptable toxicity levels can manifest themselves in higher mortality rates or unexpected intoxication effects in laboratory animals. This test makes it possible to detect abnormal (high) toxicity of a medicinal product which may be associated with degradation products or undesirable impurities resulting from changes of the production technology, which are not mentioned in specification documents related to production, transportation, and storage. In 2016—2017 12 batches of veterinary products, including vaccines and sera, were found to be noncompliant, and the Federal Service for Surveillance in Healthcare rejected 16 batches of medicinal products in 2016—2019. The aim of the study was to analyse current approaches to the ATT in the Russian and foreign pharmacopeias, and to develop a programme for phasing out the ATT use depending on the nature and pharmacological properties of medicinal products. Comparative analysis of the monographs of the world leading pharmacopeias showed that the State Pharmacopoeia of the Russian Federation has the most stringent test conditions. As an alternative to suppressing the ATT the authors suggest a phased approach to reduce the use of this test. They determined groups of medicinal products whose pharmacological properties allow for the suppression of the test. The proposed approach to phasing out the use of ATT will make it possible to use the test effectively and reduce the number of performed tests, but will still ensure drug safety. The suppression of the ATT can not be achieved without a comprehensive detailed research by quality control specialists and further discussion by all interested parties.В течение более 60 лет тест на аномальную токсичность используется как один из важных показателей при контроле качества безопасности парентеральных медицинских и ветеринарных препаратов, получаемых из субстанций биологического происхождения. В 2017 г. на заседании Фармакопейного комитета Евразийского экономического союза (ЕАЭС) было предложено не включать тест на аномальную токсичность в проект Фармакопеи ЕАЭС, основанием для данной дискуссии послужил отказ Европейской фармакопеи от данного испытания. Однако на территории нашей страны в настоящее время подобный шаг не может быть реализован, так как не все производственные площадки для производства медицинских и ветеринарных препаратов полностью отвечают международным требованиям GMP Основной целью проведения теста на аномальную токсичность является выявление токсичности препарата, превышающей установленный ранее допустимый уровень, контролируемый по повышению летальности или по неожидаемым (нерегламентированным) явлениям интоксикации животных. Данное испытание позволяет определить аномальную (повышенную) токсичность лекарственного препарата, которая может возникнуть за счет появления продуктов разложения или нежелательных примесей при изменении процесса производства, не предусмотренных регламентом производства, транспортирования или хранения. Так, в течение 2016—2017 гг. количество выявленных несоответствий ветеринарных препаратов, в том числе вакцин и сывороток, составило 12 серий, а Росздравнадзором за период 2016—2019 гг. забраковано 16 серий лекарственных препаратов. Цель работы — анализ современных подходов к тесту «Аномальная токсичность» в отечественной и зарубежных фармакопеях, разработка программы поэтапного сокращения применения теста в зависимости от природы и фармакологических свойств лекарственных средств. В результате сравнительного анализа монографий ведущих фармакопей мира установлено, что действующие требования Государственной фармакопеи Российской Федерации характеризуются наиболее строгими условиями проведения теста. В качестве альтернативы отказу от испытания на аномальную токсичность авторами предложен поэтапный подход, позволяющий сократить использование теста. Определены группы препаратов, фармакологические свойства которых позволяют исключить показатель. Предложенный поэтапный подход к сокращению использования показателя «Аномальная токсичность» позволит сделать тест более рациональным и сократить количество испытаний, но по-прежнему будет способствовать обеспечению безопасности применения лекарственных препаратов. Исключение испытания на аномальную токсичность не может быть реализовано без всесторонней детальной проработки специалистами в области контроля качества и дальнейшего обсуждения этого вопроса всеми заинтересованными сторонами
A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy
Importance Previous studies have indicated a heritable component of the etiology of neurodegenerative diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). However, few have examined the contribution of low-frequency coding variants on a genome-wide level.
Objective To identify low-frequency coding variants that affect susceptibility to AD, FTD, and PSP.
Design, Setting, and Participants We used the Illumina HumanExome BeadChip array to genotype a large number of variants (most of which are low-frequency coding variants) in a cohort of patients with neurodegenerative disease (224 with AD, 168 with FTD, and 48 with PSP) and in 224 control individuals without dementia enrolled between 2005-2012 from multiple centers participating in the Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease (GIFT) Study. An additional multiancestral replication cohort of 240 patients with AD and 240 controls without dementia was used to validate suggestive findings. Variant-level association testing and gene-based testing were performed.
Main Outcomes and Measures Statistical association of genetic variants with clinical diagnosis of AD, FTD, and PSP.
Results Genetic variants typed by the exome array explained 44%, 53%, and 57% of the total phenotypic variance of AD, FTD, and PSP, respectively. An association with the known AD gene ABCA7 was replicated in several ancestries (discovery P = .0049, European P = .041, African American P = .043, and Asian P = .027), suggesting that exonic variants within this gene modify AD susceptibility. In addition, 2 suggestive candidate genes, DYSF (P = 5.53 × 10−5) and PAXIP1 (P = 2.26 × 10−4), were highlighted in patients with AD and differentially expressed in AD brain. Corroborating evidence from other exome array studies and gene expression data points toward potential involvement of these genes in the pathogenesis of AD.
Conclusions and Relevance Low-frequency coding variants with intermediate effect size may account for a significant fraction of the genetic susceptibility to AD and FTD. Furthermore, we found evidence that coding variants in the known susceptibility gene ABCA7, as well as candidate genes DYSF and PAXIP1, confer risk for AD
Эффективность терапии туберкулеза легких с сохраненной лекарственной чувствительностью микобактерий
The article describes the study of comparative efficiency of fenazid (isonicotinoilhydrazine-О,N’) ferrous dihydrate sulphate (II) and isoniazid in drug susceptible pulmonary tuberculosis patients.The high treatment efficiency namely significant improvement and improvement was observed in the patients of Group 1 – 84.1% which could be compared to the standard treatment regimen (85-7%) in Group 2. The total number of adverse reactions in the main group was confidently lower – 18.6% against 33.9%, p < 0.05. Hepatotoxic reactions with 2-3 fold increase of alaninetransferase level was registered significantly less (9.3%) in Group 1 compared to the Group treated with isoniazid.Статья посвящена изучению сравнительной эффективности феназида (изоникотиноилгидразин-О,N’) железа (II) сульфат дигидрат и изониазида у больных туберкулезом легких с сохраненной лекарственной чувствительностью возбудителя. Получена высокая эффективность лечения «значительное улучшение» и «улучшение» у пациентов 1-й группы - 81,4%, что сопоставимо со стандартной схемой терапии (85,7%) во 2-й группе. Общее число нежелательных побочных реакций в основной группе отмечалось достоверно реже - 18,6% против 33,9%, p < 0,05. Гепатотоксические реакции с повышением в 2-3 раза уровня аланинтрансаминазы зарегистрированы значительно реже (9,3%) в I группе по сравнению с группой получавших изониазид - 23,2%
Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs
Immunomodulatory imide drugs (IMiDs) such as thalidomide, pomalidomide, and lenalidomide are the most common cereblon (CRBN) recruiters in proteolysis-targeting chimera (PROTAC) design. However, these CRBN ligands induce the degradation of IMiD neosubstrates and are inherently unstable, degrading hydrolytically under moderate conditions. In this work, we simultaneously optimized physiochemical properties, stability, on-target affinity, and off-target neosubstrate modulation features to develop novel nonphthalimide CRBN binders. These efforts led to the discovery of conformationally locked benzamide-type derivatives that replicate the interactions of the natural CRBN degron, exhibit enhanced chemical stability, and display a favorable selectivity profile in terms of neosubstrate recruitment. The utility of the most potent ligands was demonstrated by their transformation into potent degraders of BRD4 and HDAC6 that outperform previously described reference PROTACs. Together with their significantly decreased neomorphic ligase activity on IKZF1/3 and SALL4, these ligands provide opportunities for the design of highly selective and potent chemically inert proximity-inducing compounds
- …